Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

PURPOSE: Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising results in multiple tumor types. METHODS: In this random...

Descripción completa

Detalles Bibliográficos
Autores principales: Reckamp, Karen L., Redman, Mary W., Dragnev, Konstantin H., Minichiello, Katherine, Villaruz, Liza C., Faller, Bryan, Al Baghdadi, Tareq, Hines, Susan, Everhart, Leah, Highleyman, Louise, Papadimitrakopoulou, Vassiliki, Gandara, David R., Kelly, Karen, Herbst, Roy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
RAPID COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287284/
https://www.ncbi.nlm.nih.gov/pubmed/35658002
http://dx.doi.org/10.1200/JCO.22.00912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287284/
https://www.ncbi.nlm.nih.gov/pubmed/35658002
http://dx.doi.org/10.1200/JCO.22.00912

Ejemplares similares